BMI View: India's pharmaceutical market will continue to see more biosimilar products being launched by
domestic drugmakers. Developing such products is a business necessity for Indian firms to maintain
revenue growth as commoditisation limits the commercial opportuni ..."
BMI View: The tough operating environment for multinational drugmakers in India will see little
improvement over the medium term. Designated as a 'Priority Watch List Country' for PhRMA's Special
301 submission for 2016, the issues raised largely mirrored those touche ..."
BMI View: The shift in the pharmaceutical landscape due to the Trans-Pacific Partnership (TPP) will be
negative for the Indian generic drug industry. Collectively accounting for 40% of medicine exports from
India, the 12 member markets of the TPP will see stronger pat ..."
BMI View: India's pricing regime will continue to weigh on its pharmaceutical sector's growth potential.
Affecting both local and multinational pharmaceutical firms, the price cuts can be substantial, thereby
compounding the uncertainty created, especially as the deci ..."
BMI View: Internationalisation of Indian generic drugmakers will continue. This is facilitated by the
growing use of generic substitution as a tool of cost containment globally, as governments seek to curb
rising healthcare expenditure. Key risks include the difficult ..."
BMI View: The implementation of universal healthcare in India will remain challenging and we maintain
our view that a full nationwide rollout by 2019 is unlikely. This outlook is driven by the low levels of
healthcare funding provided by the government as it seeks to ..."
BMI View: India's challenging intellectual property landscape will continue to drive innovative drugmakers
to adopt risk mitigation strategies, including forming partnerships with Indian generic pharmaceuticals
companies. We highlight that such collaborations will als ..."
BMI View: The new government under Prime Minister Modi bodes well for the overall pharmaceutical
sector. The proposed introduction of universal healthcare in 2015 coupled with small regulatory reform will
help unlock the potential of the large Indian market.
BMI View: The Pharmaceutical Research and Manufacturers of America (PhRMA)'s decision to list India
as a Priority Foreign Country illustrates pharmaceutical companies' escalating discontentment with the
country due to a series of patent disrespect issues. We maintain ..."
BMI View: Pharmaceutical firms in India are reporting improved performance for the quarter
ended December 2013. This is an early indication of a recovery in the Indian pharmaceutical industry,
following the implementation of the Drug Price Control Order in May 2013. W ..."